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Background: Quality of life is an important end point in clinical trials, yet there are few quality of life questionnaires for
neuroendocrine tumours.
Methods: This international multicentre validation study assesses the QLQ-GINET21 Quality of Life Questionnaire in 253 patients
with gastrointestinal neuroendocrine tumours. All patients were requested to complete two quality of life questionnaires – the
EORTC Core Quality of Life questionnaire (QLQ-C30) and the QLQ-GINET21 – at baseline, and at 3 and 6 months post-baseline;
the psychometric properties of the questionnaire were then analysed.
Results: Analysis of QLQ-GINET21 scales confirmed appropriate aggregation of the items, except for treatment-related
symptoms, where weight gain showed low correlation with other questions in the scale; weight gain was therefore analysed as a
single item. Internal consistency of scales using Cronbach’s a coefficient was40.7 for all parts of the QLQ-GINET21 at 6 months.
Intraclass correlation was40.85 for all scales. Discriminant validity was confirmed, with valueso0.70 for all scales compared with
each other. Scores changed in accordance with alterations in performance status and in response to expected clinical changes
after therapies. Mean scores were similar for pancreatic and other tumours.
Conclusion: The QLQ-GINET21 is a valid and responsive tool for assessing quality of life in the gut, pancreas and liver
neuroendocrine tumours.
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Quality of life (QoL) is an important outcome measure in clinical
trials and is increasingly being used as an end point, especially in
studies involving patients with malignant diseases (Kavadas et al,
2003; Efficace et al, 2007). Despite this trend, a limited amount of
research has been published about QoL in patients with carcinoid
and neuroendocrine tumours (NETs) and, to our knowledge, there
are limited data on disease-specific QoL questionnaires (QLQs) for
these patients (Jacobsen and Hanssen, 1995; Wymenga et al, 1999;
Larsson et al, 1999a, b, 2001, 2003; O’Toole et al, 2000; Wareham
et al, 2002; Vinik et al, 2009).
Neuroendocrine tumours at all sites are increasing in incidence,
and the reported incidence of gastrointestinal (GI) NETs is
approaching 3 per 100 000 people per year, with a slight
predominance in women (Modlin and Sandor, 1997; Hemminki
and Li, 2001a, b; Modlin et al, 2003, 2008; Ellis et al, 2010).
Neuroendocrine tumours of gut origin may give rise to symptoms
that are related to the local presence of tumour in the gut, pancreas
or liver (e.g. pressure and pain); however, around 85% of GINETs
produce biologically active substances, which may lead to broader-
ranging symptoms and distinctive syndromes (Snow and Liddle,
1995). The most common set of symptoms are those of the
carcinoid syndrome (skin flushing, diarrhoea and wheezing) due to
excessive production of serotonin (Davis et al, 1973).
The prognosis for NET patients is dependent on both the cancer
and the syndrome, and there are differences between pancreatic
NETs and those of gut origin (Modlin et al, 2008). The overall 5-
year survival for patients with a gastroenteropancreatic NET
(following complete resection of the primary tumour and liver
metastases if present) is up to 83%; however, in many cases, where
it is not possible to surgically remove the primary NET and liver
metastases, 5-year survival ranges from 30 to 70% (Wangberg et al,
1996; Janson et al, 1997; Modlin and Sandor, 1997; Kirshbom et al,
1998; Soga, 1998; Shebani et al, 1999; Soreide et al, 2000; Wheeler
et al, 2000; Nave et al, 2001; Davies et al, 2003; Ramage et al, 2012).
Treatment should be curative where possible but is palliative in
the majority of cases (Ahmed et al, 2009), and many treatments have
side effects. It is therefore important when selecting therapies to
weigh up the benefits of treatment with its impact on the patient’s
QoL (Ramage and Davies, 2003). To assess the overall benefits of
therapeutic intervention, patient-reported outcome measures should
be included as part of clinical studies in patients with NETs, using
appropriate health-related QLQs. Generic tools to assess QoL in
cancer patients, including the EORTC Core Quality of Life
questionnaire (QLQ-C30) and the Functional Assessment of Cancer
Therapy-General (FACT-G) scale, have been developed, and may be
supplemented by disease-specific modules for different cancers
(Cella et al, 1993). Recently, the disease-specific QLQ-GINET21 was
devised to supplement the QLQ-C30 and include QoL issues
important to patients with NETs.
This paper describes an international phase 4 psychometric
validation study designed to assess the clinical and psychometric
reliability, validity and responsiveness-to-change of the QLQ-
GINET21 in patients with NETs. As discussed previously (Davies
et al, 2006), in view of the uncommon nature of pancreatic NETs
and the variety of different syndromes within this group, a
pragmatic approach has been taken to develop a disease-specific
module to cover all NETs.
PATIENTS AND METHODS
Patients. Patients were recruited into this international multi-
centre study between January 2006 and January 2010. Patients
eligible for inclusion were those aged over 18 years with either (1) a
histological diagnosis of NET or (2) radiological findings consistent
with NET together with raised hormone levels in their plasma or
urine indicative of NET. The sites of NET, with or without
hormone secretion, included any gut-primary with metastases
(including some patients who clinically had a gut primary where
the primary lesion had not been definitely identified – classified as
unknown primary), lung-primary with liver/abdominal metastases
and pancreas with or without metastases. Of the 253 patients, 124
had non-functioning tumours, secreting only chromogranin-A,
111 tumours secreted 5-hydroxy-indoloacetic acid, a main
metabolite of 5-hydroxytrptamine, four secreted gastrin, three
secreted glucagon, five secreted insulin and one secreted vasoactive
intestinal peptide. In five patients, secretion status was unknown.
Expected survival of at least 3 months and a planned treatment for
NET were also requirements for inclusion. Patients were excluded
if they had concurrent malignancy elsewhere, or had psychological,
geographical or comprehension impairment that prevented
completion of the questionnaire. Ethics committee approval and
written informed consent were obtained and the protocol was
approved by the EORTC Quality of Life Group.
Questionnaires. The study required that all patients completed two
QLQs – the EORTC core questionnaire (the QLQ-C30, version 3.0;
available at http://groups.eortc.be/qol/questionnaires_qlqc30.htm)
and the QLQ-GINET21 (see Appendix Table A1) – at all assessment
time points (baseline, and 3 and 6 months post-baseline). Details of
the development and initial field testing of the QLQ-GINET21 have
been published previously (Davies et al, 2006); however, in brief, the
QLQ-GINET21 contains a total of 21 items: four single-item
assessments relating to muscle and/or bone pain (MBP), body image
(BI), information (INF) and sexual functioning (SX), together with
17 items organised into five proposed scales: endocrine symptoms
(ED; three items), GI symptoms (GI; five items), treatment-related
symptoms (TR; three items), social functioning (SF) of the new
module (SF21; three items) and disease-related worries (DRW; three
items) (Davies et al, 2006). The response format of the questionnaire
is a four-point Likert scale. To help distinguish between missing
items and questions that are not relevant, four questions also have a
‘not applicable’ box. Responses to the QLQ-C30 and the QLQ-
GINET21 were linearly transformed to a 0–100 scale using EORTC
guidelines, with higher scores reflecting more severe symptoms.
The QLQ-GINET21 was translated into nine languages
according to strict EORTC translation guidelines (Cull et al, 2002).
Study design. Patients were assigned to one of two groups
depending on the treatment they were to receive. Group 1
consisted of 88 patients who received somatostatin (SMS)
analogues or interferon therapy; Group 2 consisted of 165 patients
who received other forms of therapy, namely peptide-receptor
radiotherapy (102 patients), chemotherapy (23 patients), surgery
(20 patients) or ablative/other therapies (20 patients). Patients
completed the QLQs before commencement of treatment (base-
line) and at 3 and 6 months post-baseline. Owing to the different
nature of the treatments, post-baseline assessments were made
during long-term continuous treatment in Group 1, while in
Group 2 some of the treatments were single administrations and
therefore the assessments occurred during the course of therapy in
only some cases. Patients also completed a number of established
debriefing questions to determine the acceptability of the module.
Test–retest reliability was assessed in 48 clinically stable patients 2
weeks after the 6-month assessment.
Statistical analysis
Reliability of the QLQ-C30 and QLQ-GINET21. The reliability (i.e.
internal consistency) of the multi-item questionnaire scales was
assessed by Cronbach’s a coefficient (Cronbach and Warrington,
1951). As recommended by Nunnally and Bernstein (1994),
internal consistency estimates of40.70 were considered acceptable
for group comparisons. The test–retest reliability approach was
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used to assess repeatability and reproducibility of the questionnaire
in a group of 48 patients (the first 48 patients who agreed to take
part). These patients completed the questionnaire again, 14 days
later; to be included in the analysis, patients in this subgroup had
to have stable disease with no change in symptoms within the
2-week period between questionnaires. Intraclass correlations
(ICCs) for the QLQ-C30 and QLQ-GINET21 scales were
calculated as a measure of test–retest reliability.
Validity of the QLQ-C30 and QLQ-GINET21. Multitrait scaling
was employed to examine the hypothesised scale structure of the
QLQ-GINET21. To test for item-scale convergence validity,
correlations between an item and its own scale of X0.40 (i.e. the
correlation coefficient) were used (Hays et al, 1988). Support for
item-discriminant validity was based on a comparison of an item
with its own scale as compared with other scales. An item was
expected to correlate significantly better (two times the standard
error) with its own scale than with other scales.
Correlation among the scales of QLQ-GINET21 and QLQ-C30
was examined using Pearson’s product–moment correlation. It was
expected that the scales that were conceptually related would
correlate substantially with one another (Pearson’s r40.40).
The Mann–Whitney U-test (equivalent to the Wilcoxon’s rank-
sum test) was used to assess known-group comparisons that
discriminate between subgroups of NET patients (e.g. functioning
vs non-functioning NETs, different primary tumour sites) with
differing clinical status (Karnofsky Performance Status). To
evaluate whether the QLQ-GINET21 could be used for pancreatic
tumours, comparisons between the mean baseline scores of
patients with pancreatic tumours and those with tumours at other
sites were performed.
Responsiveness of the QLQ-C30 and QLQ-GINET21 tools to
clinical change of health status over time was evaluated using the
three sets of questionnaires for each patient over time. The variation
of mean QoL scores over time for items and scales reflects changes in
QoL and performance status. This was not correlated with
radiological response in this study. The mean change over time
and cancer NET group was compared by repeated-measure ANOVA.
The statistical software program SPSS 18 was used for the
purpose of data management and linear transformation of
responses from the QLQ-C30 and the QLQ-GINET21 to a 0–100
scale using EORTC guidelines and SPSS syntax programming.
Stata 11 was employed for all analyses and a conservative P-value
of 0.01 was considered statistically significant. Where items were
missing, the method proposed in the EORTC scoring manual to
impute missing values was used (Fayers et al, 2001).
Sample size. A sample of 253 patients (which covered 5%
attrition), each responding to 21 items, achieves 80% power to
detect the difference between the coefficient a under the null
hypothesis of 0.60, and the coefficient a under the alternative
hypothesis of 0.71, using a two-sided F-test with a significance level
of 0.01 (Bonett, 2002). The sample size calculation is compatible
with the accepted ‘rule of thumb’ that at least 10 responses per item
are needed (Tabachnik and Fidel, 1993); therefore, the minimum
sample would be 210.
Table 1. Baseline patient characteristics
Country UK
The
Netherlands
Poland Denmark Sweden Italy Germany Spain Israel Greece
All
Patients
No. of patients
recruited
106 37 36 20 16 11 10 8 7 2 253
Age, years
Mean 63 60 56 56 61 58 64 50 59 67 60
Median 63 62 58 63 63 60 65 53 60 67 62
Range 28–83 33–75 33–74 23–77 42–84 41–71 48–78 34–64 39–76 63–71 23–84
Females, n (%) 54 (51) 14 (39) 20 (56) 12 (60) 9 (56) 4 (36) 3 (30) 2 (25) 3 (43) 1 (50) 122 (48)
Site, n (%)
Appendix 2 (2) 1 (3) 0 (0) 1 (5) 0 (0) 0 (0) 1 (10) 0 (0) 1 (14) 0 (0) 6 (2)
Colon 14 (13) 3 (8) 2 (6) 0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 1 (14) 0 (0) 21 (8)
Duodenum 2 (2) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1)
Ileum 51 (48) 7 (19) 13 (36) 5 (25) 9 (56) 3 (27) 4 (40) 2 (25) 1 (14) 0 (0) 95 (38)
Lungs 4 (4) 1 (3) 0 (0) 0 (0) 1 (6) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0) 7 (3)
Ovary
(metastatic
from ileal)
1 (1) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (1)
Pancreas 11 (10) 8 (22) 16 (44) 8 (40) 5 (31) 7 (64) 5 (50) 5 (63) 3 (43) 2 (100) 70 (28)
Stomach 1 (1) 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (1)
Unknown
(clinically gut
primary)
20 (19) 15 (41) 4 (11) 6 (30) 0 (0) 0 (0) 0 (0) 1 (13) 1 (14) 0 (0) 47 (19)
Treatment group, n (%)
Group 1 54 (51) 5 (14) 0 (0) 4 (20) 10 (63) 5 (45) 2 (20) 5 (63) 3 (43) 0 (0) 88 (35)
Group 2 52 (49) 32 (86) 36 (100) 16 (80) 6 (37) 6 (55) 8 (80) 3 (37) 4 (57) 2 (100) 165 (65)
Karnofsky performance status
Mean 82 92 84 87 86 98 84 85 90 95 86
Median 80 90 85 90 90 100 85 85 90 95 90
Range 50–100 80–100 70–90 60–100 80–90 90–100 70–90 60–100 90–90 90–100 50–100
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For the purpose of test–retest reliability, a sample size of 48
subjects with two observations per subject provides 82% power to
detect a 10% difference in ICC of 0.90 using an F-test with a
significance level of 0.05 (Walter et al, 1988).
RESULTS
Participating centres and patient characteristics. Participating
centres in the United Kingdom, the Netherlands, Poland, Den-
mark, Sweden, Italy, Germany, Spain, Israel and Greece together
enroled 253 NET patients who fulfilled the inclusion criteria (see
Appendix Table A2). Some differences in patient characteristics
and treatment approaches between centres were noted at baseline
(Table 1).
Scale construction. The scaling analysis confirmed the aggrega-
tion of items into scales, with the exception of TR, which required
revision. The TR scale had three items (question 39, side effects;
question 40, repeated injections; question 46, weight gain (WG)),
with WG being included to account for SMS analogue treatments.
WG, however, showed low correlation with the other questions in
the scale and Cronbach’s a coefficient was 0.29 (i.e. very weak);
thus, WG was removed from the TR scale and analysed as a single
item.
Completion rates and questionnaire acceptability. In total, 660
questionnaires were available for analysis. The completion rate was
90% at 3 months (227 out of 253 patients attended their
appointment, 5 had died, 18 were lost to follow-up and 3 were
too unwell) and 71% at 6 months (180 out of 253 patients attended
their appointment, 8 had died, 54 were lost to follow-up, four did
not comply and 7 were too unwell).
For the QLQ-C30, missing answers ranged from none for
question 4 to 15 for question 18, with around half of the missing
answers being from patients in the United Kingdom. For the QLQ-
GINET21, missing answers ranged from 2 for question 44 to 26 for
question 46, with most missing answers being from patients in
Italy. There was no difference in mean Karnofsky Performance
Status score between attendees and non-attendees at 3 months
(83.5 vs 86.0; P¼ 0.28) or 6 months (85.2 vs 86.0; P¼ 0.72).
Debriefing results. Of the 253 patients in the study, 209 filled in
the debriefing questionnaire, 94 (45%) did so at the outpatient
clinic, 59 (28%) at home and 56 (27%) elsewhere. The mean
reported completion time for the QLQ-C30 and QLQ-GINET21
together was about 15min, with 107 patients (52%) saying the total
time was o10min, 67 (32%) saying it took 11–15min and 29
(14%) reporting a 415min completion time; 6 patients (3%) did
not answer this question. Overall, 199 patients (95%) completed
both questionnaires in o20min. Thirty-nine patients (19%)
needed help to fill in the questionnaires, usually (in 33 cases)
from a family member.
Thirteen patients (6%) found one or more items confusing or
difficult to answer. These included questions 11, 26, 27, 29–33, 36,
45, 46 and 50 (see Appendix Table A1). Thirty-one patients (15%)
found at least one question to be not relevant.
QLQ-GINET21 scale structure: reliability and test–retest
reliability. The internal consistency of the QLQ-C30 and QLQ-
GINET21 scales was calculated overall and at each time point
separately (Table 2). Cronbach’s a coefficients for all scales in the
QLQ-C30 met the threshold of 0.70 (range 0.70–0.92) at baseline
and improved consistently over time, with the exception of nausea
and/or vomiting (NV), which decreased to 0.62 and 0.56 at the
3- and 6-month follow-ups, respectively. In the QLQ-GINET21, TR
had the lowest a coefficient at baseline (0.49) but improved over
time and reached the threshold of 0.70 at 6 months. DRW had an
overall a coefficient of 0.87 and reached 0.93 at 6-month follow-up.
Reliability analysis was also carried out on the subgroup of
patients with a pancreatic primary tumour; the Cronbach’s a
coefficient for the QLQ-C30 scales ranged from 0.80 to 0.89, and
for the QLQ-GINET21 it was 0.80 for the ED, 0.79 for the GI, 0.54
for the TR, 0.57 for the SF21 and 0.83 for the DRW scales.
ICCs were calculated for 48 individuals who filled out the
6-month questionnaires two times (once at the 6-month visit and
again 2 weeks later). All ICCs for the QLQ-C30 were40.90, except
those for the second global functioning score (QL2; 0.82), cognitive
functioning (CF; 0.86), NV (0.79), dyspnoea (DY; 0.77), sleep
disturbance (SL; 0.89) and constipation (CO; 0.85). The ICCs for
the QLQ-GINET21 were also40.90, except for the single items of
WG (0.84), MBP (0.87) and INF (0.87) (Table 2). Although an ICC
X0.90 is ideal for discriminating between groups of patients in a
clinical trial setting, an ICC X0.70 is acceptable (Fayers, 2004).
Construct validity. For both questionnaires, all items had
correlations 40.40 with their own scales (0.58–0.91), supporting
item-convergent validity. Correlations between items and other
scales were o0.40 ( 0.05 to 0.36), with the exception of the
correlation of the SF21 scale with questions 34, 41, 43 and 47
(r¼ 0.45, 0.53, 0.64 and 0.50, respectively), and the correlation of
the DRW scale with question 42 (r¼ 0.63), supporting item-
discriminant validity. Item-discriminant validity was also con-
firmed by all new module scales having correlations o0.70 with
each other.
Clinical validity. The mean QLQ-GINET21 scale scores at
baseline, and at 3 and 6 months post-baseline for different NETs
are shown in Table 3. The variation in mean scores over time for
items and scales can be regarded as a measure of responsiveness.
Changes for each scale and symptom were assessed over time
and are shown in Figure 1, according to treatment group. There
was a clear improvement in the ED scale for Group 1 (SMS
analogues and interferon) from baseline to 3 months, with some
worsening between 3 and 6 months; Group 2 also showed some
improvement; however, the GI scale did not change over time in
Group 1, but improved in Group 2 (all other treatments). There
was little change in the TR scale over time in either treatment
group. Interestingly, both SF21 and DRW improved only in Group
2. SX worsened over time in Group 1 but improved in Group 2. BI
was worse in Group 2 at the 6-month time point, whereas there
were no notable changes over time in Group 1. Other changes over
time were small. Overall, the mean change of the QLQ-GINET21
scales over time was statistically significant for ED (P¼ 0.0012), GI
(P¼ 0.0081), SF21 (P¼ 0.0065), DRW (Po0.0001) and borderline
for BI (P¼ 0.0488). Differences in mean scores between treatment
Group 1 (SMS analogues and interferon) and Group 2 (all other
treatments) were borderline statistically significant for GI
(P¼ 0.0544), TR (P¼ 0.0833), SF (P¼ 0.0067), DRW
(P¼ 0.0438) and BI (P¼ 0.0699), and not significant for all other
scales and items.
The ability of the QLQ-GINET21 to assess differences between
groups at a specific time point was examined using Karnofsky
Performance Status scores at baseline classified into two groups
(o80 and X80). The difference in QLQ-GINET21 score of
different scales between the above-mentioned Karnofsky groups
was evaluated by the Mann–Whitney U-test. The results showed
that the QLQ-GINET21 was able to assess differences between the
two Karnofsky groups, showing statistically significant results for
ED, GI, TR, SF21, DRW, MBP, SX and BI scales (in all cases,
Po0.001), and for INF (P¼ 0.0029), but not for WG (P¼ 0.869).
Similar significant results were found for the majority of core
QLQ-C30 questionnaire scales: QL2, physical functioning (PF2),
CF, SF and NV (in all cases, Po0.0001), role functioning (RF2;
P¼ 0.0002), emotional functioning (EF; P¼ 0.0026), fatigue
(FA; P¼ 0.0194), pain (PA; P¼ 0.001), DY (P¼ 0.0002),
SL (P¼ 0.0004), CO (P¼ 0.033), but not for appetite loss
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(AP; P¼ 0.557), diarrhoea (DI; P¼ 0.50) or financial difficulties
(FI; P¼ 0.105).
In addition to the known-group analyses, the mean scores of
scales in the QLQ-C30 and QLQ-GINET21 at baseline, and at
3 and 6 months were described. Using repeated-measure ANOVA,
the difference in the mean scores between pancreatic NETs and
those of other origins were investigated (Table 3).
For the QLQ-C30, overall, only the mean score for the DI scale
was statistically significantly different (Po0.0001); borderline
significance was found for SL (P¼ 0.0376) between pancreatic
and other NETs. The mean change in values over time (baseline,
and 3 and 6 months) was strongly significant for the scales of CO
(P¼ 0.0067), DI (P¼ 0.0017) and NV (P¼ 0.002), but borderline
for EF (Po0.05) and AP (P¼ 0.03).
For patients with pancreatic cancer, mean scales of the QLQ-
C30 were higher than patients with non-pancreatic cancer for QL2
(65 vs 64), RF2 (75 vs 71), CF (83 vs 81) and SF (77 vs 74),
and were lower for PA (25 vs 26), DY (16 vs 20), DI (17 vs 35),
SF21 (35 vs 38), MBP (29 vs 30), SX (32 vs 35) and INF (8 vs 12).
There was no statistically significant difference between these two
groups of primary sites in any of the scales in the QLQ-GINET21.
All correlations between the QLQ-C30 and the QLQ-GINET21
scales were o0.70, except for SF21, which for both scales was
 0.70 (Table 4).
DISCUSSION
The QLQ-GINET21 was conceived as a tool that could combine
scales and single items that assess clinically meaningful QoL
parameters. In practice, it might be useful to review each item
separately to identify specific problems experienced by individual
patients. As a research tool, however, it may be preferable to
summarise the items in clinically appropriate scales to reduce the
amount of data to be analysed and communicated. This validation
study found the proposed scale structure of the QLQ-GINET21
questionnaire to be appropriate, with the exception of the WG
item, which did not correlate well with the other items in the TR
scale. Therefore, a scale structure that includes five scales and five
single items was instead validated (Table 2). The scales
demonstrate a good degree of internal consistency, with high
Cronbach’s a coefficients for all items, except for TR and SF21,
which did not meet the threshold of 0.70 at baseline. The SF21
scale in the QLQ-GINET21 is a new type of scale, in which
questions are ordered to assess how difficult SF is for the patient.
The SF scale in the QLQ-C30 correlated quite highly with the SF21
scale in the QLQ-GINET21, confirming that both scales measure
and assess similar aspects of the same problem. The SF21 scale in
the QLQ-GINET21, however, seems to be sufficiently different to
the SF scale in the QLQ-C30 for it to provide additional
information; for example, it was more responsive to changes in
SF that occurred over time. None of the other scales in the QLQ-
GINET21 and QLQ-C30 showed high correlation, thus confirming
that the QLQ-GINET21 provides additional information to the
more generic QLQ-C30 tool. Scales/items within the QLQ-
GINET21 that correlated moderately with each other were DRW,
SF21 and SX, and one might therefore argue that these could be
combined into one scale; however, because they may respond
differentially to different NET therapies, it appears reasonable to
keep them separate.
There was reasonably good compliance with the questionnaires
and few missing items.
Changes in scores over time are to be expected. With SMS
analogues and interferon, the ED scale for Group 1 was improved
at 3 months from baseline but not at 6 months, as might be
expected with initial improvement followed by tolerance to the
SMS analogues. The GI symptoms did not improve in Group 1,
which might be expected since SMS analogues can cause some GI
symptoms as well as cure them; other therapies (Group 2) seemed
Table 2. Evaluation of internal consistency of the QLQ-GINET21 and QLQ-C30 scales
Cronbach’s a
Scales Baseline 3 months 6 months Overall No. of items ICCa
QLQ-C30
QL2 0.92 0.91 0.94 0.92 2: q29, q30 0.82
PF2 0.82 0.83 0.78 0.82 5: q1–q5 0.96
RF2 0.89 0.91 0.89 0.90 2: q6, q7 0.95
EF 0.87 0.87 0.88 0.88 4: q21–24 0.92
CF 0.70 0.77 0.73 0.73 2: q20, q25 0.86
SF 0.85 0.85 0.87 0.86 2: q26, q27 0.91
FA 0.87 0.86 0.86 0.87 3: q10, q12, q18 0.91
NV 0.74 0.62 0.56 0.68 2: q14, q15 0.79
PA 0.89 0.83 0.92 0.88 2: q9, q19 0.95
QLQ-GINET21
ED 0.73 0.70 0.74 0.73 3: q31–33 0.92
GI 0.71 0.77 0.79 0.75 5: q34–38 0.96
TR 0.49 0.62 0.71 0.62 2: q39, q40 0.95
SF21 0.62 0.64 0.70 0.65 3: q42, q44, q49 0.95
DRW 0.84 0.83 0.93 0.87 3: q41, q43, q47 0.91
Abbreviations: AP¼ appetite loss; BI¼body Image; CF¼ cognitive functioning; CO¼ constipation; DI¼diarrhoea; DRW¼disease-related worries; DY¼dyspnoea; ED¼endocrine symptoms;
EF¼ emotional functioning; FA¼ fatigue; FI¼ financial difficultie; GI¼gastrointestinal symptoms; ICC¼ intraclass correlation; INF¼ information; MBP¼muscle and/or bone pain; NET¼
neuroendocrine tumour; NV¼nausea and/or vomiting; PA¼pain; PF2¼physical functioning; QL2¼global health; RF2¼ role functioning; SF¼ social functioning; SF21¼ social functioning of
the new module; SL¼ sleep disturbance; SX¼ sexual functioning; TR¼ treatment-related symptoms; WG¼weight gain. (1) For the QLQ-C30: q8, DY (ICC¼ 0.77); q11, SL (ICC¼ 0.89); q13 AP
(ICC¼ 0.90); q16, CO (ICC¼ 0.85); q17, DI (ICC¼ 0.96); and q28, FIs (ICC¼ 0.95) (2) For the QLQ-GINET21: q45, BI (ICC¼ 0.92); q46, WG (ICC¼ 0.84); q48, MBP (ICC¼ 0.87); q50, INF (ICC¼ 0.87);
and q51, SX ( ICC¼ 0.90).
aICC (test–retest reliability statistics) for single items.
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to improve GI symptoms. DRW and SF21 improved only in Group
2, suggesting the use of a definitive treatment other than SMS
analogues improved patients’ psychosocial issues. The change in
SX was different in the two groups and might imply an adverse
effect of SMS analogues, although this would need further studies
for confirmation.
The scales within the QLQ-GINET21 were more sensitive to
differences between patient subgroups (as determined by patients’
Karnofsky Performance Scores) and more responsive to changes
over time than were the scales in the QLQ-C30. These properties
might be considered the most important aspects of any clinical
research tool, and highlight the importance of including disease-
specific QoL assessments within clinical trials. The QLQ-GINET21
is designed to be used together with the existing QLQ-C30, and
jointly they may provide a reliable tool that is useful for a broad
evaluation of QoL in clinical studies of patients with GINETs.
The baseline QoL values for patients, as measured by both
questionnaires, showed that there were variations between centres,
which could be explained by differences in patient selection and
patient characteristics (primary tumour site, tumour stage
and baseline Karnofsky Performance Status). At baseline, all scales
and single items seemed to distinguish between subgroups of
patients on the basis of Karnofsky Performance Status. There was
no correlation between Karnofsky Performance Status and the
single item of WG in the QLQ-GINET21, which would be expected
as, in the context of cancer, WG resulting from treatment would
not be related to low functional status. Similarly, in the QLQ-C30,
as might be expected, there was no correlation between Karnofsky
Performance Status and the items of FI and CO; however,
surprisingly, there was also a lack of correlation with DI, which is
Table 3. QLQ-GINET21 scale mean scores at baseline, and at 3 and 6 months post-baseline, by cancer type
Pancreas Unknown and other primaries
Scales Baseline 3 months 6 months Baseline 3 months 6 months
QLQ-C30
QL2 61 67 67 62 65 66
PF2 79 79 78 79 78 80
RF2 71 76 78 71 70 73
EFa 69 75 73 71 75 75
CF 83 84 83 81 82 81
SF 74 80 78 72 74 78
FA 36 34 32 35 34 35
NVa 14 10 9 13 8 8
PA 28 24 21 30 25 24
DY 16 18 14 20 21 20
SL 37 38 38 32 27 30
APa 24 18 16 20 14 12
COa 17 15 16 15 8 10
DIab 22 12 15 40 32 31
FI 19 21 24 18 20 15
QLQ-GINET21
EDa 22 16 18 25 19 20
GIa 26 18 22 26 23 23
TR 18 22 23 15 15 18
SF21a 39 33 30 41 36 35
DRWa 56 44 50 54 44 41
MBP 25 31 32 30 30 30
SX 32 31 31 36 33 36
INF 10 4 10 13 11 10
BIa 25 21 19 24 21 16
WG 11 9 13 11 10 10
Abbreviations: AP¼ appetite loss; BI¼body Image; CF¼ cognitive functioning; CO¼ constipation; DI¼diarrhoea; DRW¼disease-related worries; DY¼dyspnoea; ED¼endocrine symptoms;
EF¼ emotional functioning; FA¼ fatigue; FI¼ financial impact; GI¼gastrointestinal symptoms; INF¼ information; MBP¼muscle and/or bone pain; NET¼ neuroendocrine tumour; NV¼
nausea and/or vomiting; PA¼pain; PF2¼physical functioning; QL2¼global health; RF2¼ role functioning; SF¼ social functioning; SF21¼ social functioning of the new module; SL¼ sleep
disturbance; SX¼ sexual functioning; TR¼ treatment-related symptoms; WG¼weight gain.
aThe mean change over time was borderline significant for EF (P¼ 0.0459), AP (P¼ 0.0376) and BI (P¼ 0.0223), and strongly significant for NV (P¼ 0.0037), CO (P¼ 0.009), DI (P¼ 0.0025), ED
(P¼ 0.0001), GI (P¼ 0.0013), SF21 (P¼ 0.0006) and DRW (Po0.0001).
bThe difference in the diarrhoea scale mean was statistically significant, with Po0.001 between two groups. None of the mean scales in the QLQ-GINET21 module was statistically significant
between pancreatic and other NETs.
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Figure 1.QLQ-GINET21 scale and single-item mean scores at baseline,
and at 3 and 6 months post-baseline (x axis: scale/item; y axis: mean
score). The subscripts of 1 and 2 represent Group 1 and Group 2,
respectively.
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common to many GINETs and would be expected to be associated
with a poorer performance status.
The data on most scales and single items of the QLQ-GINET21
were skewed toward low values, but responses covered the full
range of scores for most of the new scales at all evaluation time
points, thus confirming the response categories are appropriate.
Importantly, the QLQ-GINET21 was well accepted by patients;
across all 660 questionnaires evaluated, the rate of missing values
was p2%, with the exception of question 40 (relating to repeated
injection), where the rate of missing values was 7%, and question
51 (relating to sex life), where it was 5%. The fact that 91% of
patients answered the questionnaires at the second time point was
as expected, and the lower value of 71% at the third time point was
not ideal but was similar to what has been found in other large
multicentre validation studies.
The data comparing tumours of different origin suggest that the
QLQ-GINET21 can be used for pancreatic as well as non-
pancreatic NETs, although it is accepted that pancreatic numbers
were too small for a proper validation in patients with this tumour
type alone.
CONCLUSION
The QLQ-GINET21 has been confirmed in this phase 4 validation
study to have a module structure and scales that are clinically
sensitive, reliable and valid. We recommend that this disease-
specific module is used in randomised clinical trials of therapies,
which would give further information on its clinical utility; indeed,
some such trials are already in progress.
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APPENDIX
Table A1. EORTC QLQ-GINET21
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Centre Name Number Enroled Percentage
UK centres:
Basingstoke 32 12.7
Cardiff 2 0.8
Christie 5 2.0
Imperial College 4 1.6
Kings College 15 5.9
Liverpool 24 9.5
Belfast 5 2.0
Newcastle 7 2.8
Royal Free 9 3.6
Southampton 3 1.2
International
countries:
Netherlands:
Rotterdam 31 12.3
Amsterdam 6 2.4
Table A2. (Continued )
Centre Name Number Enroled Percentage
Poland: Warsaw 36 14.2
Denmark:
Copenhagen
20 7.9
Sweden: Uppsala 16 6.3
Italy:
Palma 5 2.0
Verona 6 2.4
Germany: Berlin 10 4.0
Spain: Madrid 8 3.2
Israel: Jerusalem 7 2.8
Greece: Athens 2 0.8
Total 253 100
Table A2. Participating centres
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